GenexGen

Executive Summary

GenexGen is a preclinical-stage biotechnology company pioneering epigenetic therapies to address previously undruggable immune pathways. Its core technology employs mRNA-encoded epigenetic repressors to silence disease-driving genes, starting with MYD88 for hyperinflammatory conditions. The lead program targets hemophagocytic lymphohistiocytosis (HLH), a rare and fatal orphan disease with no approved targeted therapies. By leveraging epigenetic silencing, GenexGen aims to achieve durable modulation of immune responses while minimizing off-target effects, potentially transforming treatment paradigms for HLH and broader chronic inflammatory and age-related immune dysfunctions. The company's platform is designed for rapid, programmable gene silencing, positioning it to address multiple indications with high unmet need. GenexGen operates in Cambridge, MA, within a vibrant biotech ecosystem. While still in early stages, the company's approach has attracted interest due to its potential to overcome limitations of conventional gene therapies and small molecules. Upcoming milestones include advancing the HLH program toward clinical development and validating the platform in additional inflammatory conditions. With a strong scientific foundation and a clear focus on orphan and chronic diseases, GenexGen represents a high-risk, high-reward opportunity in the epigenetic therapeutics space. Key risks include early stage of development, lack of clinical data, and competitive landscape.

Upcoming Catalysts (preview)

• H2 2026IND/CTA Filing for HLH Program40% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data in Peer-Reviewed Journal70% success
• Q2 2026Orphan Drug Designation from FDA for HLH Program80% success